MENU
IBRN
ETF ticker: NYSE ARCA
PRICE
CHANGE
NET ASSETS

IBRN stock forecast, quote, news & analysis

The investment seeks to track the NYSE FactSet Global Neuro Biopharma and MedTech Index composed of U... Show more

Category: #Health
IBRN
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for IBRN with price predictions
Sep 11, 2026

IBRN sees MACD Histogram just turned negative

IBRN saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on August 28, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 40 instances where the indicator turned negative. In 33 of the 40 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 82%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on August 31, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IBRN as a result. In 60 of 74 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.

IBRN moved below its 50-day moving average on September 08, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBRN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

The Aroon Indicator for IBRN entered a downward trend on August 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where IBRN's RSI Indicator exited the oversold zone, 16 of 18 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +2.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where IBRN advanced for three days, in 167 of 212 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

IBRN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Biogen (NASDAQ:BIIB), Intra-Cellular Therapies (NASDAQ:ITCI), Sarepta Therapeutics (NASDAQ:SRPT), Avadel Pharmaceuticals plc (NASDAQ:AVDL).

Industry description

The investment seeks to track the NYSE FactSet Global Neuro Biopharma and MedTech Index composed of U.S. and non-U.S. companies that could benefit from the growth and innovation in neuroscience. The fund will invest at least 80% of its assets in the component securities of its index and in investments that have economic characteristics that are substantially identical to the component securities of its index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents as well as in securities not included in the index, but which BFA believes will help the fund track the index.

Market Cap

The average market capitalization across the iShares Neuroscience and Healthcare ETF ETF is 5.01B. The market cap for tickers in the group ranges from 107M to 62.16B. ARGX holds the highest valuation in this group at 62.16B. The lowest valued company is SAVA at 107M.

High and low price notable news

The average weekly price growth across all stocks in the iShares Neuroscience and Healthcare ETF ETF was -4%. For the same ETF, the average monthly price growth was -5%, and the average quarterly price growth was 21%. EWTX experienced the highest price growth at 3%, while DYN experienced the biggest fall at -25%.

Volume

The average weekly volume growth across all stocks in the iShares Neuroscience and Healthcare ETF ETF was 54%. For the same stocks of the ETF, the average monthly volume growth was 15% and the average quarterly volume growth was -40%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 60
P/E Growth Rating: 71
Price Growth Rating: 49
SMR Rating: 89
Profit Risk Rating: 80
Seasonality Score: 2 (-100 ... +100)
View a ticker or compare two or three
IBRN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Details
Category
Health
Address
iShares Trust400 Howard StreetSan Francisco
Phone
1-800-474-2737
Web
www.ishares.com